Stifel Financial Corp Has $16.57 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Stifel Financial Corp lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 223,857 shares of the medical research company's stock after selling 8,881 shares during the quarter. Stifel Financial Corp's holdings in Edwards Lifesciences were worth $16,572,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Wellington Management Group LLP raised its position in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC lifted its stake in Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $610,895,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 1.2 %

NYSE:EW opened at $76.06 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The firm's fifty day moving average is $70.94 and its 200-day moving average is $71.07. The firm has a market cap of $44.71 billion, a P/E ratio of 10.91, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same quarter in the prior year, the firm posted $0.66 earnings per share. Equities analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday. Piper Sandler upgraded shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their target price for the company from $73.00 to $80.00 in a research report on Thursday. Finally, Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and an average target price of $79.45.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,853 shares of company stock worth $5,163,062. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.